Icon
+91 94997 68112
Login Register

Lumigan - (0.01%; Solution/Drops, Opthalmic)

Bimatoprost Allergan
0.01%; Solution/Drops, Opthalmic
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
LUMIGAN 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Yes
****** ** *** *** * **** ** **** ****** '*** *** '*** *** *** ************ *********. ******** ***** ***** **** *** ******* ** ***** & ********* ** *** ********. **** **** ** *** ******** *** ****** *** ******* ****** *** **, ****. * *** ****** ***. *********- **** **, **** *** ****** ** ********. ***** ****** ***** **** ** **** ****** '*** *** *** ********* ** ******** **** ******* '*** & '***. ******* **** ******** ***** *** ******* ******* **** *** ****** '*** (*** **, ****), '*** (***** **, ****), '*** (***** **, ****), '*** (***** **, ****), '*** (***** **, ****). **** **** ** *** ******** *** ***** ****** *** **, ****. ******, ***** *** ********* ******** * ********* ******** **** *** *** **** *** **** *** *********. ** ****** **** ***** * **** *** ** ******* ******** ** *** **** *** *** ** *** ****.
Lumigan Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12
****** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******)
***** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******)
**-**** ****** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** **** ** ** *** ** *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******) *** ********* (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* *** **, **** **** ** ** *** ** ********* ******** ** *** **, ****
***** ** \ ** *** **, **** **** ** ** *** ** **** ** *** **, ****
**-**** ****** ** \ ** *** **, **** **** ** ** *** ** **** ** *** **, ****
  1. *** **, **** : ****** ******** ******** ***** *** **** ** ****** **** ******* '*** *** '***
  2. *****, **** : **** ******** ******** ***** *** ****** ****** **** ******* *** ******* ******* & *******.
  3. ***, **** : ******** ***** * **** ******* **** ** ******** ***** ** ********.
  4. *** **, **** : ******** ***** * **** ******* ****** ** ******** ***** ** ********.
  5. *** **, **** : ******** ***** * **** ******* ***** ** ***** ***** **** ** **** ****** '***.
  6. *** *, **** : **-**** ******** ******** ** *** ****-** ******* **** ****** '***
  7. *** **, **** : * *** ****** ***. ********* *** ****** ** ********.
  8. *** **, **** : ******** **** **-**** **** ************ ** ****** '***
  9. **** *, **** : ***** ***** **** *** ******* ** ***** & ********* ** *** ********.
  10. *** **, **** : ****** ******** ******** ***** *** **** ** **** ******* *** ****** '***.
  11. *** **, **** : ******** ***** * **** ******* ****** **** ******* '*** ** ******** ***** ** ******* ******** ** *****.
  12. *** *, **** : ******** **** ******, *****, **-**** *** ****** **** ************ ** ***** ****** ******* ’***, ’***, ’***, *** ’***
  13. *** *, **** : ****** ******** ********* ******** *** *** *** *********
  14. *** *, **** : ******** ***** **** ******* '*** (*** **, ****), '*** (***** **, ****), '*** (***** **, ****), '*** (***** **, ****), '*** (***** **, ****) ** ***** *** ********* ** ********.
  15. *** *, **** : ******* ******* ******** ******** *****'* ********.
  16. *** **, **** : ***** ****** ******** ********* ******** *** *** *** *********
  17. *** **, **** : ********* ******** ********* ******** *** **** *** *** *** *********.
  18. *** **, **** : ******* ******** ******** ** *** ****-** ****** **** ****** '***
  19. *** **, **** : ******** **** ******* **** ************ ** ****** '***
  20. *** **, **** : ******** *** ******* ******* ********** **** ****** '*** ********.
  21. *** **, **** : ***** *** ******** *** ******* ********** ******* ******** *** *******.

Lumigan - (0.03% Solution/ Drops; Ophthalmic)

Bimatoprost Allergan
0.03% Solution/ Drops; Ophthalmic
Less Than $1000 mn
Less Than 5
More Than 5
More Than 5
 None
More Than 5
More Than 5
Lumigan (bimatoprost) lowers pressure in the eye by increasing the amount of fluid that drains from the eye. Lumigan eye drops are used to treat certain types of glaucoma and other causes of high pressure inside the eye
Yes
****** *** *** ***** ** **** **** ** **** ******* ******* - *** **, **** ; ******* - *** **, **** & ******* - *** **, **** *** *** ************ *********. ** ****** **** **** ****** ******* *** ****. ******* **-**** **** ***** * **** ** **** ****** ******* *** *** ************ *********.
  1. **** **, **** : ****** ******** ******** ***** *** **** ** ****** *** ******* '***, '*** & '***.
  2. *** **, **** : ******** ***** * **** ******* ****** ** ******* ******** ** *****.
  3. *** **, **** : **-**** ******** ******** ***** *** **** ** ****** *** ****** '*** ** ******* ******** ** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.